n a landmark development for global cancer care, Cipla Limited (BSE: 500087; NSE: CIPLA EQ), a leading global pharmaceutical company, today announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for
Pharma firm Cipla and Kemwell Biopharma on Wednesday announced the execution of a joint ventureagreement to develop, manufacture and commercialise biosimilars for global markets. For this purpose, a joint venture company shall be incorporated with an aim to enter the respiratory biosimilars space, Cipla said
Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk* of severe COVID-19Roche India and Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced
Strengthens offerings & continues to be at the forefront of COVID care Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems
